Dan Atar

Upcoming event: Cardio-Oncology should have broad interest across multiple disciplines: event.checkin.no/225253/bhc-nor… Participation is free of charge.

I am deeply honored by the occasion to receive the “outstanding research article 2025” award from our hospital OUS, for our BETAMI-DANBLOCK article in the NEJM. This was huge teamwork, and I thanked the co-workers at OUS/UiO, my co-Chair, and the entire CV community in NO & DK.

A great honor to welcome @ESC_President Thomas Lüscher to Bergen and the NCS Spring Meeting. His talk on AI and the future of cardiovascular medicine was truly thought-provoking. (Take a look at the Elon Musk quote on the first photo🫣)

Glad to present online-streaming of JCS2026 with the session on guideline-changing evidence. On demand streaming Site: congre.co.jp/jcs2026/en/ Streaming Login: e416mb A special thanks to Prof. Koichi Node, JCS2026-Chair, and Prof. Shinya Goto, my amazing host and co-Chairman.

Impressions from Japan. 🇯🇵 The view from outer space shows how Japan illuminates Asia.

Such an incredible experience: to be invited to the JCS2026, the Japanese Circulation Society, in beautiful Fukuoka. A marvelous congress with over 10.000 attendees. A huge thank you to Prof. Koichi Node, the Congress Chair. And likewise to my host, Prof. Shinya Goto.

Arrived in Tokyo. Huge hospitality @ Tokai University Hospital, by my friend Prof. Shinya Goto, a world renowned clinical scientist. Amazing experience just prior to embarking on the Shinkansen bullet train from Odawara to Fukuoka. My warmest thanks for this incredible reception.

Rethinking β-blockers after MI Our @NEJM Editorial integrates evidence from two recent IPD meta-analyses and outlines the emerging paradigm for β-blockade after MI. 
👉 nejm.org/doi/full/10.10… ➡️ Time for personalized secondary prevention @Borjaibanez1 @dan_atar @DLBHATTMD

CVCT stands out as a unique and most exciting “different” kind of conference where involvement across all stakeholders is key. Huge congratulations to Faiez Zannad and Javed Butler to such a great achievement. Honored to be back as faculty and to contribute to science.

At #CVCT2025 I reviewed the nonlinear basic discovery arc underlying clinical development from autologous #CDCs #postMI to #deramiocel for #Duchenne #cardiomyopathy culminating in the blockbuster #HOPE3 trial by @Capricor. Odyssean journey! @SmidtHeart @CIRMnews @CoalitionDMD

@MarbanLab @rblument1 @CIRMnews @NIH @CoalitionDMD @rrogerslab @A22002Mark @SmidtHeart My sincere congratulations. It comes just in time after your magnificent Honorary Lecture at the AHA.

A 21 year journey of invention, discovery and mechanistic investigation yields the first therapy shown to improve both heart and skeletal muscle function in #Duchenne muscular dystrophy. @CIRMnews @NIH @CoalitionDMD @rrogerslab @A22002Mark @SmidtHeart

#CVCT2025: Beta-blockers post-MI have been discussed for the last 50 years. Early trials firmly documented survival benefits, but the entire landscape has changed. Contemporary trials now provide clear answers. Join us, December 8-10, Washington DC: lnkd.in/dyg5BMwm #CVCT

And here with the registration link: ESC 365 - Are beta-blockers still indicated after myocardial infarction?   myesc.escardio.org/MyESC/s/event-…

Any HCP who is involved in post-MI care: this ESC Webinar may be of interest to you: #Oslo Center for Clinical Heart Research # Escardio webinars

@evandrofilhobr @DrPascalMeier Wonderful 👏

Great photo @DrPascalMeier

@Hragy Likewise, such a pleasure.

@dan_atar at Graz Cardiac Summit - a real pleasure to meet again:)